Claudine Bruck
Director/Board Member bij ANNOVIS BIO, INC.
Vermogen: 78 147 $ op 31-03-2024
Profiel
Claudine E.
Bruck is the founder and currently holds the position of Chairman at Prolifagen LLC, which was founded in 2016.
She is also currently serving as an Independent Director at Annovis Bio, Inc. since 2015 and as the Chief Scientific Officer at SapVax LLC.
In her former positions, Dr. Bruck served as an Independent Director at Navidea Biopharmaceuticals, Inc. from 2018 to 2021.
She also held the position of Course Director at the University of Pennsylvania, Head-Cancer Vaccine Program at GlaxoSmithKline LLC, and Assistant Professor at Tufts University School of Medicine.
Dr. Bruck obtained a doctorate degree from Vrije Universiteit Brussel and a graduate degree from Harvard Medical School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ANNOVIS BIO INC
0.06% | 20-11-2023 | 6 567 ( 0.06% ) | 78 147 $ | 31-03-2024 |
Actieve functies van Claudine Bruck
| Bedrijven | Functie | Begin |
|---|---|---|
| ANNOVIS BIO, INC. | Director/Board Member | 01-01-2015 |
| Prolifagen LLC | Founder | 01-06-2016 |
SapVax LLC
 SapVax LLC Pharmaceuticals: MajorHealth Technology SapVax LLC develops a platform for generating peptide-based, self-adjuvanting cancer vaccines. Its platform is based on a flexible synthetic method for linking tumor antigens with an adjuvant, which enables the generation of vaccines targeting virtually any peptide tumor antigen. The company was founded by Rod Dunbar and Margaret Brimble in 2016 and is headquartered in Cleveland, OH. | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Claudine Bruck
| Bedrijven | Functie | Einde |
|---|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Director/Board Member | 14-09-2021 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
| University of Pennsylvania | Corporate Officer/Principal | - |
| Tufts University School of Medicine | Corporate Officer/Principal | - |
Opleiding van Claudine Bruck
| Vrije Universiteit Brussel | Doctorate Degree |
| Harvard Medical School | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Health Technology |
| ANNOVIS BIO, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
SapVax LLC
SapVax LLC Pharmaceuticals: MajorHealth Technology SapVax LLC develops a platform for generating peptide-based, self-adjuvanting cancer vaccines. Its platform is based on a flexible synthetic method for linking tumor antigens with an adjuvant, which enables the generation of vaccines targeting virtually any peptide tumor antigen. The company was founded by Rod Dunbar and Margaret Brimble in 2016 and is headquartered in Cleveland, OH. | Health Technology |
| Prolifagen LLC |
